Sorin rejects analysts' forecast of divestment
This article was originally published in Clinica
Executive Summary
Sorin has dismissed speculation that it may divest its renal care business. Analysts at Morgan Stanley Dean Witter distributed a report on the Italian biomedical company last month which said: "Although [the renal care business] is profitable and generates cash, we believe, based on the company's stated strategy, that Sorin would entertain exiting the business if the right opportunity, for example an attractive cardiovascular surgery business, came along."
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.